PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA

Bibliographic Details
Main Authors:	J.-F. Bai, J. T. Li, R. Feng, L. Qian, J. Yin, H. Liu
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000851220.50282.7c

PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9)
by: J. Westin, et al.
Published: (2022-06-01)

PB2149: ZANUBRUTINIB IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB VERSUS R-MINICHOP IN UNFIT OR FRAIL PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA AGED OVER OR EQUAL TO 70 YEARS
by: P. Xu, et al.
Published: (2022-06-01)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Xiyuan Zhang, et al.
Published: (2023-08-01)

2097
by: Matthew Thomas Rondina, et al.
Published: (2017-09-01)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
by: Giulia Bega, et al.
Published: (2021-12-01)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Xianggui Yuan, et al.
Published: (2022-11-01)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
by: Silvana Novelli, et al.
Published: (2023-08-01)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
by: Antonio Salar Silvestre, et al.
Published: (2023-08-01)

S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY
by: W. Townsend, et al.
Published: (2022-06-01)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
by: Yanan Zhu, et al.
Published: (2022-09-01)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
by: Yue Teng, et al.
Published: (2023-08-01)

Zanubrutinib Combined with Rituximab and Methotrexate for Treatment of Primary Central Diffuse Large B-cell Lymphoma: A Case Report
by: LI Wenhui, et al.
Published: (2023-08-01)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
by: Laurie H. Sehn, et al.
Published: (2020-06-01)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
by: Antonio Cuneo, et al.
Published: (2020-11-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
by: Bellone M, et al.
Published: (2021-07-01)

P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY
by: T. Abuasab, et al.
Published: (2022-06-01)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
by: A. Haujir, et al.
Published: (2022-06-01)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
by: Y. Zhang, et al.
Published: (2022-06-01)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Published: (2022-06-01)

Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review
by: Tahera Alnassfan, et al.
Published: (2022-02-01)

Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
by: Regina Pileckyte, et al.
Published: (2019-10-01)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
by: Chang-Ju Qu, et al.
Published: (2023-08-01)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
by: Y. Tang
Published: (2022-06-01)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
by: Jun Zhu, et al.
Published: (2022-11-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
by: Zhiguang Lin, et al.
Published: (2023-08-01)

P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
by: M. Welslau, et al.
Published: (2022-06-01)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
by: H. Zhu, et al.
Published: (2022-06-01)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
by: William Townsend, et al.
Published: (2023-07-01)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
by: Benoit Tessoulin, et al.
Published: (2023-08-01)

PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: X. Wei, et al.
Published: (2022-06-01)

Urothelial carcinoma management in elderly or unfit patients
by: Joaquim Bellmunt, et al.
Published: (2016-03-01)

PB2337: SHORT-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH POMALIDOMIDE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMA
by: Zhipeng Zhang, et al.
Published: (2023-08-01)

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
by: Roland Christian Schelker, et al.
Published: (2018-10-01)

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
by: Huilai Zhang, et al.
Published: (2023-08-01)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
by: K. Ren, et al.
Published: (2022-06-01)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
by: Paolo Strati, et al.
Published: (2023-08-01)

Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System
by: María Elena Cabrera, et al.
Published: (2022-11-01)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA

Similar Items

Similar Items